Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

NCT06081959 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

376

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: SKB264
DRUG: Eribulin
DRUG: Capecitabine
DRUG: Gemcitabine
DRUG: Vinorelbine

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.